504227585 02/14/2017

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4274262

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ZHENGYING PAN	02/06/2017

RECEIVING PARTY DATA

Name:	PHARMACYCLICS LLC
Street Address:	995 E. ARQUES AVENUE
City:	SUNNYVALE
State/Country:	CALIFORNIA
Postal Code:	94085

PROPERTY NUMBERS Total: 3

Property Type	Number
Application Number:	13543065
Application Number:	13543394
Application Number:	14794685

CORRESPONDENCE DATA

Fax Number: (617)832-7000

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6179883584

Email: phenders@foleyhoag.com

Correspondent Name: PATRICIA L. HENDERSON/FOLEY HOAG LLP

Address Line 1: 155 SEAPORT BLVD.

Address Line 4: BOSTON, MASSACHUSETTS 02210-2600

ATTORNEY DOCKET NUMBER:	PIR-78010, 78011, 78022	
NAME OF SUBMITTER:	PATRICIA L. HENDERSON	
SIGNATURE:	/Patricia L. Henderson/	
DATE SIGNED:	02/14/2017	

Total Attachments: 3

source=PIR-780_ Executed Assignment from Pan#page1.tif source=PIR-780_ Executed Assignment from Pan#page2.tif source=PIR-780_ Executed Assignment from Pan#page3.tif

PATENT 504227585 REEL: 041253 FRAME: 0880

PATENT ASSIGNMENT

WHEREAS, the undersigned:

1. PAN, Zhengying Austin, TX

(hereinafter "Inventor"), have invented certain new and useful improvements in

INHIBITORS OF BRUTON'S TYROSINE KINASE

for which

Application Serial No. 11/692,870 (now U.S. Patent No. 7,732,454), was filed on March 28, 2007;

Application Serial No. 11/964,285 (now U.S. Patent No. 7,825,118), was filed on December 26, 2007;

Provisional Patent Application Serial No. 61/017,125, was filed on December 27, 2007;

PCT International Patent Application Serial No. PCT/US08/058528, was filed on March 27, 2008;

Application Serial No. 12/594,805 (now U.S. Patent No. 8,883,435), was filed on June 8, 2010;

Application Serial No. 13/543,065 (now U.S. Patent No. 9,079,908), was filed on July 6, 2012;

Application Serial No. 13/543,394 (now U.S. Patent No. 9,139,591), was filed on July 6, 2012;

Application Serial No. 14/794,685 (now U.S. Patent No. 9,556,182), was filed on July 8, 2015; and

Application Serial No. 15/412,738, was filed on January 23, 2017,

in the United States Patent and Trademark Office;

WHEREAS, <u>Pharmacyclics LLC</u>, a limited liability company organized and existing under the laws of the State of <u>Delaware</u>, having a place of business at <u>995 E. Arques Avenue</u>, <u>Sunnyvale, CA 94085</u>, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter "Patent(s)") thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor to have been received in full from said Assignee:

PATENT REEL: 041253 FRAME: 0881

- 1. Said Inventor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions, including the right to claim priority to and said Inventions; (b) in and to all rights to all United States and corresponding non-United States patent applications and Patent(s), including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise; (c) in and to any and all applications filed and any and all Patent(s) granted on said Inventions in the United States, in any foreign country, or under any international convention, agreement, protocol, or treaty, including each and every application filed and any and all Patent(s) granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); and (d) in and to each and every reissue, reexamination, or extensions of any of said Patent(s).
- Said Inventor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Inventor in providing such cooperation shall be paid for by said Assignee.
- 3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor, his respective heirs, legal representatives and assigns.
- 4. Said Inventor hereby warrants and represents that he has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 5. Said Inventor hereby requests that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

IN WITNESS WHEREOF, said Invesaid Assignee as of the dates written below:	ntor has executed and delivered this instrument to	
Date: Feb 6, 2017	Zhengying PAN	
Then personally appeared the above-named instrument to be his free act and deed, bef 2017.	d Zhengying PAN and acknowledged the foregoing ore me, this _blu_ day of _Feb,	
	Witness signature	
	Witness Name (please print)	
RECEIVED AND AGREED TO BY ASSIGNEE: PHARMACYCLICS LLC		
Date: 6 February 2017	Signature: Name/Title: Anis III, Head of Legal	
	ľ	

- 3 -